Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5625_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
17 Мб
Скачать
☆
1.2 Carbohydrate-Based Vaccines
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Table1.2  Chemical structure of CPS repeating units within serogroups or types in licensed vaccines.
Serogroup
Pathogen
or type Repeating unit
11
Haemophilus influenzae
Neisseria meningitidis
Salmonella enterica
Streptococcus pneumoniae
Type b →3)βRibf(1→1)Ribol(5OPO3→
A →6)αManpNAc(3/4OAc)(1OPO
→
3
C →9)αNeup5Ac(7/8OAc)(2→ W →6)αGalp(1→4)αNeup5Ac(7/9OAc)(2→ Y →6)αGlcp(1→4)αNeup5Ac(7/9OAc)(2→ typhi Vi →4)αGalpNAcA(3OAc)(1→
1 →3)αAATGalp(1→4)αGalpA(2/3OAc)(1→3)α
GalpA(1→ 3 →3)βGlcpA(1→4)βGlcp(1→ 4 →3)βManpNAc(1→3)αFucpNAc(1→3)αGalpNAc
(1→4)αGalp2,3(S)Pyr(1→ 5 →4)βGlcp(1→4)[αPnepNAc(1→2)βGlcpA
(1→3)]αFucpNAc(1→3)βSugp(1→ 6A →2)αGalp(1→3)αGlcp(1→3)αRhap(1→3)Rib
ol(5→OPO
→
3
6B →2)αGalp(1→3)αGlcp(1→3)αRhap(1→4)Rib
ol(5→OPO
→
3
7F →6)[βGalp(1→2)]αGalp(1→3)βRhap(2OAc)
(1→4)βGlcp(1→3)[αGlcpNAc(1→2)α
Rhap(1→4)]βGalpNAc(1→ 8 →4)βGlcpA(1→4)βGlcp(1→4)αGlcp(1→4)α
Galp(1→ 9V →4)αGlcp(2/3OAc)(1→4)αGlcpA(2/3OAc)
(1→
3)αGalp(1→3)βManpNAc(4/6OAc)(1→4)β
Glcp(1→ 10A →4)βGalpNAc(1→3)αGalp(1→2)Ribol
(5→OPO 11A →3)βGalp(1→4)βGlcp(1→6)[Gro(1→OPO
→5)βGalf(1→3)βGalp(1→
3
→4)]
3
αGlcp(3OAc)(1→4)αGalp(2OAc)(1→ 12F →4)αFucpNAc(1→3)βGalpNAc(1→4)β
ManpNAcA(1→ 14 →4)βGlcp(1→6)[βGalp(1→4)]βGlcpNAc
(1→3)βGalp(1→ 15B →6)[αGalp(2/3/4/6OAc)(1→2)[Gro(2→OPO
→3)]β
3
Galp(1→2)]βGlcpNAc(1→3)βGalp(1→4)βGlcp
(1→
(Continued)
1 Antibacterial Carbohydrate Vaccines
12
Table1.2  (Continued)
Serogroup
Pathogen
or type Repeating unit
18C →4)βGlcp(1→4)[αGlcp(6OAc)(1→2)]
19A →4)βManpNAc(1→4)αGlcp(1→3)αRhap
19F →4)βManpNAc(1→4)αGlcp(1→2)αRhap
22F →4)βGlcpA(1→4)[αGlcp(1→3)]βRhap(2OAc)
23F →4)βGlcp(1→4)[αRhap(1→2)][Gro
33F →3)βGalp(1→3)[αGalp(1→2)]αGalp(1→3)β
Abbreviations: Glc, glucose; Gal, galactose; Neu5Ac, Nacetylneuraminic acid (sialic acid); Rha, rhamnose; GlcNAc, Nacetylglucosamine; GalNAc, Nacetylgalactosamine; FucNAc, Nacetylfucosamine; ManNAcA, Nacetylmannuronic acid; PneNAc, Nacetylpneumosamine (2acetamido2,6dideoxytalose); GlcA, glucuronic acid; Gro, glycerol; Ribol, ribitol; Sug, 2acetamido2,6deoxyhexose4ulose; AATGal, 2acetamido4amino2,4,6trideoxygalactose; 2,3(S)Pyr, trans2,3(S) cyclic pyruvate ketal modification at galactose; p, pyranose form; f, furanose form; OPO3, phosphate group in phosphodiester linkages.
[Gro(1→OPO Rhap(1→
(1→OPO
(1→OPO
(1→4)αGlcp(1→3)αGalf(1→2)αRhap(1→
(2→OPO
Galf(1→3)βDGlcp(1→5)βGalf(2OAc)(1→
→3)]βGalp(1→4)αGlcp(1→3)β
3
→
3
→
3
→3)]βGalp(1→4)βRhap(1→
3
1.2.1  Mechanism ofthe Immune Response  toCarbohydrate-Based Vaccines
Bacterial CPSs have been recognized as key virulence factors for more than a cen­tury and have been explored as potential vaccine antigens from the outset[51, 52]. The licensure of the previously mentioned CPSbased vaccines against N. menin- gitidis, S. pneumoniae, H. influenzae b, and S. typhi allowed an efficient control of the disease in adults and older children, especially for shortlasting exposures (trave­lers and soldiers in military campaigns). Plain PSbased vaccines, however, are una­ble to mount a protective immune response in the immature immune systems of newborns and young children (under two years of age), who are the major group at risk for these infections. Even in adults and adolescents, PS vaccines are not able to induce memory B cells (MBCs), avidity maturation, and antibody isotype switching from immunoglobulin M (IgM) to immunoglobulin G (IgG). Most of the antibodies produced, indeed, are lowaffinity IgM, which are only poor activators of the com­plement system, a key arm of the innate immune system that enhances the humoral responses[53, 54]. Furthermore, immunization of adults and older children with PS vaccines leads to apoptosis of MBCs, thus reducing the response to subsequent administrations, a phenomenon usually referred to as hyporesponsiveness[55]. PSs are Tcellindependent type 2 (TI2) immunogens, which are typically highmass polymers with repeating structures of 5–10 nm. Due to their polymeric structure,
1.2 Carbohydrate-Based Vaccines
(b)
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
PSs activate B cells by crosslinking approximately 15–20 Bcell receptors (BCRs), triggering a series of protein phosphorylation steps which leads to an increase in free intracellular calcium (Figure1.1a)[56]. The need to crosslink multiple BCRs to achieve Bcell activation is noteworthy, as it explains the reason why the immuno­genicity of PS vaccines is sizedependent, with only highmolecularweight antigens capable of inducing an effective immune response. Following stimulatory cytokines or costimulatory signals expressed by other cells of the immune system[57–59], B cells are finally activated. They mature into plasma cells and secrete antibodies
No
immunological
memory
(a)
13
Figure1.1  Immune response following immunization with polysaccharides (a) and glycoconjugates (b).
Immunological
memory
1 Antibacterial Carbohydrate Vaccines
14
(mainly IgM) but since the entire process takes place without the direct involvement of T cells, the development of MBCs and the induction of immunological memory do not occur.
Unlike PSs, proteins and peptides are instead Tcelldependent (TD) antigens, as they stimulate helper T lymphocytes to elicit an immune response leading to spe­cific antibody response. TD antigens are immunogenic even in early childhood, the immune response induced can be boosted and enhanced by adjuvants, and it is characterized by an antibody class switch with the production of highaffinity and antigenspecific IgG. The haptencarrier concept[60] underpinning the develop­ment of glycoconjugate vaccines is based on the fact that the covalently linked pro­tein carrier confers Tcelldependent properties to the glycoconjugate, which is eventually able to produce carbohydratespecific MBCs. The molecular mechanism of the immune response to glycoconjugate vaccines has been thoroughly investi­gated[61, 62], albeit some steps are still unclear. After administration, the conjugate is taken up by antigenpresenting cells (APCs), mainly dendritic cells (DCs), but also macrophages and B cells can play the same role. Engulfment by APCs is pro­moted by stimulation of pathogen recognition receptors (PRRs), a large family of receptors expressed on APCs surface able to respond to a huge variety of pathogen associated molecular patterns (PAMPs), structurally and chemically diverse com­pounds highly conserved in pathogens but absent in their multicellular host. PRRs stimulation creates the necessary proinflammatory context (expression of costimu­latory molecules and secretion of soluble cytokines and chemokines), leading to full maturation of DCs, antigen uptake, and intracellular processing (Figure 1.1b). In particular, the glycoconjugate antigen is chopped through the intracellular endoso­mal compartments. While the saccharide portion is depolymerized by oxidative agents (reactive oxygen species, ROS, and reactive nitrogen species, RNS)[63, 64], the protein portion is processed by proteases into small peptides. Within a few days, mature DCs reach the draining lymph nodes, where peptide antigens are conveyed to the cell surface in association with the major histocompatibility complex class II (MHCII) protein to be presented to T lymphocytes via interaction with the Tcell receptor (TCR). T lymphocytes are then activated as helper T cells (Th or CD4 cells), which provide appropriate stimulatory signals to elicit a conventional TD immune response. Th cells prime the maturation process of resting B cells, driving their proliferation and differentiation into antibodysecreting (mainly IgM) plasma cells and MBCs, ensuring the establishment of the immunological memory. Contrary to plasma cells, MBCs survive for a long time in the body and respond rapidly to subsequent exposures of the same antigen by secreting highaffinity IgG antibodies.
Recent findings[65] provided more details on the mechanism of action of glyco­conjugate vaccines, highlighting the crucial role of the formation of germinal cent­ers (GCs) to elicit an immune response. GCs are sites in lymph nodes where mature Bcell proliferation and differentiation occur. The GC formation requires the pres­ence of PSspecific B cells, which display the antibody on their surface as a BCR, the follicular helper T (Tfh) cells, which are able to recognize the protein carrier anti­gen, and the follicular dendritic cells (FDCs), highly specialized APCs, which
+
T
   
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
contain and present the antigen to the B cells. The formation of GCs is an essential step during the immune response to an infection or after vaccination, since the affinity maturation process and the class switch from IgM to IgG occur in the GCs, specifically in two distinct regions called the light and dark zones.
Also, Kasper and coworkers suggested that not only peptides but also glycopep­tide fragments are generated by glycoconjugate processing in APCs and presented to TCR in the context of MHCII[66, 67]. According to this model, the lipophilic peptide portion of the glycopeptide antigen binds to MHCII, whereas the hydro­philic carbohydrate portion is exposed to the TCR, leading to the generation of carbohydratespecific Th, called T carb cells.
It should be emphasized that the different mechanisms of the immune response toward PS and glycoconjugate antigens also have practical consequences in vaccine design. Since crosslinking of surface immunoglobulin molecules on B cells is not required, glycoconjugate vaccines can also be produced from small saccharide chains obtained by size fractionation of native PSs or by chemical synthesis.
The development of glycoconjugate vaccines has been one of the greatest success stories of modern medicine [68, 69], as demonstrated by the drastic reduction of S. pneumoniae, H. influenzae b, and N. meningitidis infections in those countries where the corresponding conjugate vaccines have been introduced in routine vac­cination programs. Overall, these vaccines have had a huge impact on global infant mortality and morbidity, saving millions of lives.
15
1.3   Components ofGlycoconjugate Vaccines
A vaccine is a biological product able to induce an immune response that confers protection against an infection upon successive exposures to a pathogen[10]. The efficacy of protection is based on preexisting antibodies in the serum, which prevent the disease but not the infection[70]. Although most vaccines are based on TD pro­tein antigens, PSs can also be used to induce protective immune responses, at least in an immunocompetent host. However, as explained in Section 1.2.1, the Tcell independence of PSs prevents the proliferation of MBCs and the occurrence of immunological memory, making PSbased vaccines ineffective for infants and young children, as well as for immunocompromised individuals. Protein–PS conju­gate vaccines provided the solution to overcome these limitations, enabling the use of bacterial surface PSs as antigens to induce longlasting protection from infectious diseases. Saccharide antigens employed for the construction of glycoconjugate vac­cines are either derived from the pathogen or produced synthetically to mimic the components of the microorganism. They can be present in the form of microbial poly or oligosaccharides (OSs) (the latter obtained by sizefractionation of the native polymer) or as synthetic lowmolecularweight compounds, covalently linked to a carrier protein. In addition, subunit glycoconjugate vaccines can be for­mulated with adjuvants to enhance the low immunogenicity of carbohydrate antigens.
1 Antibacterial Carbohydrate Vaccines
16
Impressive progress has been made in the field of antibacterial vaccine develop­ment over the past two decades. Surprisingly, the important milestones that have outlined the history of antibacterial vaccines have been reached with an empirical approach[12]. The main reason is that only in recent times has immunology started to give a useful contribution to vaccine design. Recent advances in basic immunol­ogy are now unveiling the immunological principles that govern susceptibility to infections and protection of the host, ushering in the era of rational vaccine design. Indeed, progresses in vaccinology permitted us to realize that different, often inter­connected, parameters can affect the immunogenicity of the glycoconjugate. Besides the choice of the Tcell helper protein, factors more related to the design of the sac­charide antigen and its conjugation to the carrier protein have been recognized as important variables to determine immunogenicity. The elements to consider for the development of an efficient, immunogenic, and protective vaccine setting are now much clearer, and vaccinology is moving to a new era where the “vaccine” should be regarded as a pharmaceutical rather than as a biological product[71]. The follow­ing paragraphs of Section1.3 report a more detailed analysis of each key component of a glycoconjugate vaccine, highlighting how they affect the efficacy of the con­struct and the robustness of the elicited immune response.
1.3.1 The Carbohydrate Antigen
Antibacterial glycoconjugate vaccines may contain fulllength or sizereduced PSs, generally derived from CPS or the Oantigen portion of LPS. The PS portion of the construct is the key player in the glycoconjugate; indeed, the efficacy of the vac­cine is measured by the magnitude and the quality of the immune response against the carbohydrate antigen. The size, and therefore the length, of the PS fragment is the principal determinant of its immunogenicity[72]. The glycan chain of a PS con­tains epitopes or antigenic determinants, also called glycoepitopes, that are the spe­cific portions of the PS recognized by antibodies and responsible for inducing the antigenspecific immune response of the host. An epitope is commonly identified as a sequence of an average of six/seven contiguous residues (linear or branched), but for long saccharide chains, conformational epitopes are also formed, where discon­tinuous monosaccharide units closely organized in space are simultaneously engaged by the BCRs[73].
The lesson from traditional plain PS vaccines is that the large size of the PSs ensures crosslinking of multiple BCRs to elicit the TI immune response. The pres­ence of repetitive antigenic determinants increases the avidity of antibody–antigen binding, thus facilitating the activation of B cells even when they express lowaffinity antibodies[74]. On the other hand, the immunological mechanism of glycoconju­gate vaccines does not depend exclusively on crosslinking of BCRs. In glycoconju­gates, the simultaneous exposition of multiple copies of shorter PS fragments covalently attached to the carrier protein triggers the activation of the immune response. Yet, also in this case, a relationship between the length of the protein conjugated PS fragment and the immunogenicity of the vaccine persists.
   
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Consequently, significant efforts are aimed at determining the minimal OS length capable of maintaining the epitope determinants required to engage the antibody and elicit a Tcelldependent protective immune response. However, the correlation between these two parameters depends on the type of glycoconjugate produced[72]. Typically, sizereduced PSs are obtained through chemical or mechanical fragmenta­tion of the natural PSs isolated from cultures of pathogenic bacteria, followed by multiple purification and characterization steps to reduce glycan heterogeneity[75]. The use of more defined saccharide fragments facilitates the conjugation with the protein carrier and allows for improved batchtobatch consistency of the final glyco­conjugate. PS fragments are then conjugated to the protein either randomly, through the hydroxyl or carboxyl groups occurring along the saccharide chain, or via func­tional groups localized at the glycan end of the sugar chain (typically the anomeric carbon of the reducing end monosaccharide)[37]. The latter methodology generally includes the use of a linker to facilitate the glycan–protein coupling and to alleviate the steric hindrance between protein and saccharide (see Section1.3.2). The two dif­ferent strategies lead to heterogeneous crosslinked structures, usually involving multiple saccharide chains and protein molecules, and more defined structures with a radial exposition of saccharide chains endterminal conjugated to a single protein molecule, respectively. The manufacture of random crosslinked conjugates uses PS fragments of about 100–300 of the sugar is carried out on shorter fragments of 5–20
kDa, while the selective attachment at the reducing end
kDa, generally referred to as OSs[76]. Studies in the literature support the observation that higher immunogenic­ity of endlinked glycoconjugates correlates with the use of mediumsize OSs, while longer PS fragments are preferable in obtaining randomly crosslinked effective gly­coconjugates. As an example, a study in mice using endlinked conjugate preparation of Salmonella enterica sv typhi Vi antigen coupled to crossreacting material 197 (CRM197) showed that shorter chain constructs (glycan size about 9.5 kDa) induced a more prolonged proliferation of Vispecific B cells and a slower decline of Vi specific IgG antibodies compared to their longer chain counterparts (glycan size about 165
kDa)[77]. On the other hand, a study on crosslinked glycoconjugates of Francisella tularensis OAgs coupled to tetanus toxoid (TT) evidenced that a geneti­cally induced, veryhighmolecularsize OAg (around 220 kDa) provided a marked increase in protection. The LPSspecific antibodies induced by this largersized Oantigen exhibit significantly enhanced relative affinity compared to low and native molecular weight preparations (25 and 80 kDa, respectively), albeit with comparable antibody titers[78]. This study supports the importance of conformational OAg epitopes in the protection induced by the vaccine.
The shape of the glycoconjugate and the way the glycoconjugates are presented to the immune system are critical and interconnected aspects of vaccine efficacy. In this regard, the carbohydratetoprotein ratio is considered a significant parameter. Hib PS fragments with different chain lengths were coupled to diphtheria toxin (DT) car­rier protein. The average degree of polymerization (avDP) was 8 or 20monosaccha­ride RUs, and a maximum of three sugar moieties per protein molecule were conjugated[79]. The shorter avDP8 oligomer stimulated a poorer anticarbohydrate
17
1 Antibacterial Carbohydrate Vaccines
18
response than the avDP20, but immunogenicity comparable to the avDP20 oligomer was then obtained in a later study where four/five sugar fragments with avDP8were coupled to TT, thus supporting the argument that a higher level of protein glycosyla­tion could compensate the shorter chain length[80].
The evidence that even a short OS chain can induce the production of specific antibodies that can protect the host from a pathogen and current advances in OSs synthesis have opened a new era of vaccine research that aims to prepare the carbo­hydrate antigen by chemical synthesis[81]. Structurally defined synthetic OSs, designed based on molecular understanding of antigen–antibody interactions, offer a promising alternative for developing semisynthetic (containing fully synthetic car­bohydrates conjugated to an immunogenic carrier protein) and fully synthetic gly­coconjugate vaccines based on synthetic OS antigens conjugated to synthetic carrier molecules, such as glycolipids or peptides[82–84]. The access to the active compo­nents of the vaccines by chemical synthesis, made possible by the tremendous pro­gresses and recent technological innovations in glycan assembly[85–95], would result in more reproducible and homogeneous vaccine preparations, characterized by robust biological properties and better safety profile. Accordingly, the manufac­turing process of the glycoconjugates thus obtained would be facilitated and accel­erated, enabling timely combat of emerging or antimicrobial‐resistant infectious diseases and/or addressing currently unmet medical needs[71, 96].
One additional aspect to consider when investigating carbohydrate antigens for immunological applications is that the size and structure of the PS can be affected by the manufacturing process. The production of the PS is designed to improve the yields and consistency of the final product. For example, native CPSs are com-
–1
monly isolated by bacterial culture. The yield (expressed in xmgl
, where x are mg of pure CPSs extracted from 1 l of culture broth) and the molecular weight of bacte­rial PS produced during fermentation are influenced by the genetic nature of the microorganism and the fermentation conditions (i.e. the carbohydrate source and the carbon/nitrogen ratio in the culture medium, pH, and temperature)[78, 97–99]. Other factors influence the consistency of the final products: the type of PS frag­mentation (i.e. chemical or mechanical), the size‐fractionation and purification processes, and the activation chemistry before conjugation. Due to the highly spe­cific mechanism for immunological activation, it is important to reduce extensive chemical modifications of the native PS structure during the production of the glycoconjugates. For example, the loss of labile O‐acetyl groups, which are present (often in random order) in different PSs, might impair the immunogenicity of a PS, leading to a less effective vaccine. In this regard, the meningococcal NeisVac‐C vac­cine, which uses de‐O‐acetylated MenC OSs[100], shows less efficacy than other licensed MenC glycoconjugate vaccines, like Menjugate, that are derived from acetylated OS. Also, the random periodate oxidation of the vicinal hydroxy groups of the PS units to generate multiple aldehyde groups to be reacted with the protein by reductive amination should be tightly controlled to affect only some monosac­charides in order to avoid extensive PS chemical modification and, consequently, the loss of immunogenicity.
   
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
1.3.2  Linkers forCarbohydrate–Protein Conjugation
In glycoconjugate vaccines, the covalent conjugation of the saccharide antigen to the carrier protein can be achieved either directly or through short linear spacer molecules, called linkers. The introduction of a linker facilitates the coupling of the glycan to the protein because the steric hindrance that may reduce the reactivity between two relatively large molecules is reduced. In addition, the presence of a linker affects the spatial orientation of the glycan epitopes around the protein and the way they are presented to the immune system. Indeed, the nature of the linker and the type of conjugation chemistry are other key factors in the development of a vaccine candidate. They are interconnected and have to be considered jointly because the conjugation chemistry should be based on a highly efficient chemose­lective coupling step between two specific functional groups on the carbohydrate and the protein[61]. On one side, there are the chemically reactive sites of the car­bohydrate moiety, which are mostly (i) aldehyde groups obtained by periodate oxi­dation of cisdiols in the sugar ring or at the glycerol moiety of sialic acid residues, (ii) carboxyl groups of sialic or uronic acid residues, (iii) cyanate esters generated by random functionalization of the sugar hydroxyls with cyanilating agents, and (iv) primary amino groups, generally obtained by an end terminal reductive amination of sized OSs. Bacterial OS fragments obtained by chemical synthesis are generally designed with short linkers at their reducing end bearing a terminal reactive group suitable for protein conjugation, such as an amine, a thiol, an alkyne, or an azide. On the other side, the common protein functional groups that are more suitable for chemical linkage to sugars are the carboxylic groups of aspartic and glutamic acid residues and the εamino group of lysines. These amino acid residues are generally well exposed on the surface of the protein, thanks to their hydrophilic character. Based on the functional groups that are present on the two coupling partners, the protein and the glycan, different types of linkers have been developed over the last 30
years[37].
Homobifunctional linkers contain the same reactive group at the two ends. The gly­coconjugate construct is generally obtained through a twostep protocol, which involves the initial coupling of one of the two partners in the presence of an excess of the linker, followed by the conjugation of the activated intermediate to the second part­ner moiety. The Di(Nsuccinimidyl)adipate (DSA) and the dithiopropionates Dithio bis(succinimidylpropionate) (DSP) and Dithiobis(sulfosuccinimidylpropionate) (DTSSP) are examples of linkers containing two terminal carboxyls activated as N hydroxysuccinimidyl (NHS) esters, which react with the amino groups of the lysine residues on the protein and of the sugar to give stable nonhydrolyzable amide bonds (Figure1.2) . Chemical conjugation through stable chemical bonds can also be obtained by exploiting the cystamine or ADH homobifunctional linkers that contain two amino or hydrazide functional groups at both ends, respectively (Figure 1.2). These are crosslinking reagents able to engage aspartic and glutamic residues on the protein in an EDCmediated coupling, while they can give reductive amination with the formyl groups on the sugar or be employed in nucleophilic additions to cyanide groups to form
19
1 Antibacterial Carbohydrate Vaccines
2,5-dihydro-1H-pyrrol-1-yl)-propanoate
20
Homobifunctional linkers
O
N
O
Di-(N-succinimidyl)-adipate
S u g a
r
R
O
O
N
NH
2
OS
O
R = H DSP Dithiobis(succinimidylpropionate)
Na DTSSP
R = SO
3
Dithiobis(sulfosuccinimidylpropionate)
O
OO
N
( )
OO
4
DSA
S
O
O
OO
EtO OEt
Diethyl Squarate
O
P
H2N
r
o
t
e
O
N
R
O
i
n
HOOC
H2N
HS
N3 or CCH
OH
P
r
o
t
e
i
n
P
r
o
t
e
i
n
Sugar
O
O
Protein
O
O
Sugar/Protein
NH
O
N
ON
O
2,5-dioxopyrrolidin-1-yl-3-(2,5-dioxo-
2
O
O
O
SH
Sugar/Protein
S
COOH
u
CHO
g a
CN
r
S
NH
u
2
g
SH
a
r
3,3-bis(bromomethyl)oxetane
Heterobifunctional linkers
SH
SN
2,5-dioxopyrrolidin-1-yl-3-
(pyridin-2-yldisulfanyl)-propanoate
NH
2
H
N
2
H2N
ADH: Adipic acid hydrazide
S
S
Cystamine
OO
( )
N H
O
Br
N
Br
O
Dibromomaleimide
Br
Br
O
OS
N
O
O
NH
NH
N
4
H
CH
3
O
N
1,2,4-triazole­3,5(4H)-dione
2
2
O
N
R =
N
R
O
Figure1.2  Representative examples of homo- and heterobifunctional linkers for glycoconjugation.
N
3
O
O
amidine bonds. All these homobifunctional linkers are soluble in water and ensure highly specific and easy conjugation protocols that have been exploited in the prepara­tion of different glycoconjugate vaccines[101-103]. Diethyl squarate also reacts with amino groups on the sugar and the protein to give crosslinked coupling products[104]. Halogen bearing homofunctional spacers, such as dibromomaleimide or 3,3 bis(bromomethyl)oxetane, are also available (Figure1.2). They are characterized by a cyclic scaffold and by the presence of two halogens that can be displaced in a twostep